Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Multi-pass membrane protein |
Domain |
PF00003 7 transmembrane sweet-taste receptor of 3 GCPR PF01094 Receptor family ligand binding region PF07562 Nine Cysteines Domain of family 3 GPCR |
Function |
G-protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis (PubMed:7759551, PubMed:8702647, PubMed:8636323, PubMed:8878438, PubMed:17555508, PubMed:19789209, PubMed:21566075, PubMed:22114145, PubMed:23966241, PubMed:25292184, PubMed:25104082, PubMed:26386835, PubMed:25766501, PubMed:22789683). Senses fluctuations in the circulating calcium concentration and modulates the production of parathyroid hormone (PTH) in parathyroid glands (By similarity). The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system (PubMed:7759551). The G-protein-coupled receptor activity is activated by a co-agonist mechanism: aromatic amino acids, such as Trp or Phe, act concertedly with divalent cations, such as calcium or magnesium, to achieve full receptor activation (PubMed:27434672, PubMed:27386547). |
Biological Process |
GO:0001503 ossification GO:0005513 detection of calcium ion GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0007635 chemosensory behavior GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0044708 single-organism behavior GO:0051592 response to calcium ion GO:0055074 calcium ion homeostasis GO:0070509 calcium ion import GO:0070838 divalent metal ion transport GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport |
Molecular Function |
GO:0004435 phosphatidylinositol phospholipase C activity GO:0004620 phospholipase activity GO:0004629 phospholipase C activity GO:0008081 phosphoric diester hydrolase activity GO:0016298 lipase activity GO:0042578 phosphoric ester hydrolase activity |
Cellular Component | - |
KEGG |
hsa04621 NOD-like receptor signaling pathway |
Reactome |
R-HSA-420499: Class C/3 (Metabotropic glutamate/pheromone receptors) R-HSA-418594: G alpha (i) signalling events R-HSA-416476: G alpha (q) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-500792: GPCR ligand binding R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR |
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CASR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CASR in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CASR in various data sets.
|
Points in the above scatter plot represent the mutation difference of CASR in various data sets.
|
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CASR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CASR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CASR. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CASR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CASR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CASR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CASR |
Name | calcium-sensing receptor |
Aliases | FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ...... |
Chromosomal Location | 3q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CASR collected from DrugBank database. |
Details on drugs targeting CASR.
|